Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018


August 31, 2011
113 Pages - SKU: GBDT6518433
License type:
Table of Contents Search inside this report Related Reports
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Anemia Therapeutics - Introduction
2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.4 Symptoms
2.5 Diagnosis
2.5.1 Physical Examination
2.5.2 Complete Blood Count (CBC)
2.5.3 Other Tests and Procedures
2.6 Treatment and Management Pattern
2.6.1 Dietary Changes and Supplements
2.6.2 Medicines
2.6.3 Medical Procedures
2.7 GlobalData Pipeline Report Guidance
3 Anemia Therapeutics - Market Characterization
3.1 Anemia Therapeutics Market Size (2005-2010) - Global
3.2 Anemia Therapeutics Market Forecast (2010-2018) - Global
3.3 Anemia Therapeutics Market Size (2005-2010) - The US
3.4 Anemia Therapeutics Market Forecast (2010-2018) - The US
3.5 Anemia Therapeutics Market Size (2005-2010) - France
3.6 Anemia Therapeutics Market Forecast (2010-2018) - France
3.7 Anemia Therapeutics Market Size (2005-2010) - Germany
3.8 Anemia Therapeutics Market Forecast (2010-2018) - Germany
3.9 Anemia Therapeutics Market Size (2005-2010) - Italy
3.10 Anemia Therapeutics Market Forecast (2010-2018) - Italy
3.11 Anemia Therapeutics Market Size (2005-2010) - Spain
3.12 Anemia Therapeutics Market Forecast (2010-2018) - Spain
3.13 Anemia Therapeutics Market Size (2005-2010) - The UK
3.14 Anemia Therapeutics Market Forecast (2010-2018) - The UK
3.15 Anemia Therapeutics Market Size (2005-2010) - Japan
3.16 Anemia Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Anemia Therapeutics Market
3.17.1 Drivers for the Anemia Market
3.17.2 Barriers for the Anemia Market
3.18 Opportunity and Unmet Need Analysis
3.18.1 Opportunity and Unmet Need for Erythropoietin Stimulating Agents (ESA)
3.18.2 Opportunity and Unmet Need for Iron Supplements:
3.19 Key Takeaway
4 Anemia Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.2.1 Competitor Assessment Within Different Therapeutic Categories Employed in Anemia Treatment:
4.3 Product Profile for the Major Marketed Products in the Anemia Market
4.3.1 Aranesp (darbepoetin alfa)
4.3.2 Mircera (methoxy polyethylene glycol-epoetin beta)
4.3.3 Biopoin/Eporatio (epoetin theta)
4.3.4 Epogen/Procrit/Eprex (epoetin alfa)
4.3.5 Epogin/Neorecormon (epoetin beta)
4.3.6 Bio-Similar Erythropoietins
4.3.7 Oral Iron Supplements
4.3.8 Feraheme (ferumoxytol)
4.3.9 Ferinject/Injectafer (ferric carboxymaltose)
4.3.10 Venofer/Fesin (iron sucrose)
4.3.11 Monofer (iron isomaltide)
4.3.12 Cosmofer/InFed/Ferrisat (iron dextran)
4.3.13 Ferrlecit (sodium ferricgluconate complex)
4.3.14 Immunosuppressive Agents
4.3.15 Vitamin Supplements
4.4 Key Takeaway
5 Anemia Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Anemia Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Anemia Therapeutics - Filed Pipeline
5.3.2 Anemia Therapeutics - Phase III Pipeline
5.3.3 Anemia Therapeutics - Phase II/III Pipeline
5.3.4 Anemia Therapeutics - Phase II Pipeline
5.3.5 Anemia Therapeutics - Phase I/II Pipeline
5.3.6 Anemia Therapeutics - Phase I Pipeline
5.3.7 Anemia Therapeutics - Preclinical Pipeline
5.3.8 Anemia Therapeutics - Discovery Pipeline
5.4 Anemia Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Anemia Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 Hematide (peginesatide)
5.7.2 ST10-021
5.7.3 Soluble Ferric Pyrophosphate (SFP)
5.8 Key Takeaway
6 Anemia Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Anemia Therapeutics Clinical Trials
7 Anemia - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Anemia Therapeutics - Implications for Future Market Competition
8 Anemia Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 F. Hoffmann-La Roche Ltd.
8.2.2 Affymax, Inc.:
8.2.3 3SBio Inc.:
8.2.4 Kyowa Hakko Kirin Co., Ltd:
8.2.5 Shield Therapeutics
8.2.6 Pharmacosmos A/S
8.2.7 Amgen Inc.
8.2.8 Johnson & Johnson
8.2.9 Millennium - The Takeda Oncology Company
8.2.10 Galenica Ltd.
8.2.11 Rockwell Medical Technologies, Inc.
8.2.12 Other Companies in the Anemia Market
9 Anemia Therapeutics - Licensing and Partnership Deals
10 Anemia Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Anemia Therapeutics Market, Global, Market ($bn), 2005-2010
Table 2: Anemia Therapeutics Market, Global, Forecast ($bn), 2010-2018
Table 3: Anemia Therapeutics Market, The US, Market ($bn), 2005-2010
Table 4: Anemia Therapeutics Market, The US, Forecast ($bn), 2010-2018
Table 5: Anemia Therapeutics Market, France, Market ($m), 2005-2010
Table 6: Anemia Therapeutics Market, France, Forecast ($m), 2010-2018
Table 7: Anemia Therapeutics Market, Germany, Market ($m), 2005-2010
Table 8: Anemia Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 9: Anemia Therapeutics Market, Italy, Market ($m), 2005-2010
Table 10: Anemia Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 11: Anemia Therapeutics Market, Spain, Market ($m), 2005-2010
Table 12: Anemia Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 13: Anemia Therapeutics Market, The UK, Market ($m), 2005-2010
Table 14: Anemia Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 15: Anemia Therapeutics Market, Japan, Market ($m), 2005-2010
Table 16: Anemia Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 17: Anemia Therapeutics - Filed Pipeline, 2011
Table 18: Anemia Therapeutics - Phase III Pipeline, 2011
Table 19: Anemia Therapeutics - Phase II/III Pipeline, 2011
Table 20: Anemia Therapeutics - Phase II Pipeline, 2011
Table 21: Anemia Therapeutics - Phase I/II Pipeline, 2011
Table 22: Anemia Therapeutics - Phase I Pipeline, 2011
Table 23: Anemia Therapeutics - Preclinical Pipeline, 2011
Table 24: Anemia Therapeutics - Discovery Pipeline, 2011
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart
Table 26: Anemia Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 27: Anemia Therapeutics - Clinical Trials by Country, 2011
Table 28: Anemia Therapeutics - Clinical Trials by Phase, 2011
Table 29: Anemia Therapeutics - Clinical Trials by Status, 2011
Table 30: Anemia Therapeutics - Prominent Sponsors, 2011
Table 31: Anemia Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 32: F. Hoffmann-La Roche Ltd. - Hematology Pipeline
Table 33: F. Hoffmann-La Roche Ltd. - Anemia Pipeline
Table 34: F. Hoffmann-La Roche Ltd. - Deals
Table 35: Affymax, Inc. - Hematology Pipeline
Table 36: Affymax, Inc. - Anemia Pipeline
Table 37: 3SBio Inc. - Hematology Pipeline Portfolio, 2011
Table 38: 3SBio Inc. - Anemia Pipeline
Table 39: 3SBio Inc. - Deals
Table 40: Kyowa Hakko Kirin Co., Ltd. - Hematology pipeline products, 2011
Table 41: Kyowa Hakko Kirin Co., Ltd. - Anemia Pipeline
Table 42: Kyowa Hakko Kirin Co., Ltd. - Deals
Table 43: Shield Therapeutics - Hematology Pipeline
Table 44: Pharmacosmos A/S - Hematology Pipeline
Table 45: Pharmacosmos A/S - Deals
Table 46: Amgen Inc. - Hematology Pipeline
Table 47: Amgen Inc. - Anemia Pipeline
Table 48: Amgen Inc. - Deals
Table 49: Johnson & Johnson - Hematology Pipeline
Table 50: Johnson & Johnson - Deals
Table 51: Millennium: The Takeda Oncology Company - Hematology Pipeline
Table 52: Millennium: The Takeda Oncology Company - Deals
Table 53: Galenica Therapeutics- Hematology Pipeline, 2011
Table 54: Galenica Ltd- Deals, 2011
Table 55: Rockwell Medical Technologies, Inc. - Hematology Pipeline, 2011
Table 56: Other Future Players in the Anemia Therapeutics Market
Table 57: Anemia Therapeutics, Licensing and Partnership Deals
1.2 List of Figures
Figure 1: Physiologic Classification of Anemia
Figure 2: Classification of Anemia According to World Health Organization (WHO) - International Classification of Disease (ICD)
Figure 3: Laboratory Tests Conducted in Complete Blood Count (CBC) Diagnostic Test
Figure 4: Therapy Options for Anemia
Figure 5: Anemia Therapeutics Market, Global, Revenue ($bn), 2005-2010
Figure 6: Anemia Therapeutics, Market Share ($m), 2005
Figure 7: Anemia Therapeutics Market, Global, Forecast ($bn), 2010-2018
Figure 8: Anemia Therapeutics, Market Share ($m), 2010
Figure 9: Anemia Therapeutics Market, The US, Market ($bn), 2005-2010
Figure 10: Anemia Therapeutics Market, The US, Forecast ($bn), 2010-2018
Figure 11: Anemia Therapeutics Market, France, Market ($m), 2005-2010
Figure 12: Anemia Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 13: Anemia Therapeutics Market, Germany, Market ($m), 2005-2010
Figure 14: Anemia Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 15: Anemia Therapeutics Market, Italy, Market ($m), 2005-2010
Figure 16: Anemia Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 17: Anemia Therapeutics Market, Spain, Market ($m), 2005-2010
Figure 18: Anemia Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 19: Anemia Therapeutics Market, The UK, Market ($m), 2005-2010
Figure 20: Anemia Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 21: Anemia Therapeutics Market, Japan, Market ($m), 2005-2010
Figure 22: Anemia Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 23: Opportunity and Unmet Need for Erythropoietin Stimulating Agents in the Anemia Therapeutics Market, 2011
Figure 24: Opportunity and Unmet Need for Iron Supplements in the Anemia Therapeutics Market, 2011
Figure 25: Anemia Therapeutics - Strategic Competitor Assessment of Erythropoietin Stimulating Agents, 2011
Figure 26: Anemia Therapeutics - Strategic Competitor Assessment of Iron Supplements, 2011
Figure 27: Anemia Therapeutics - Pipeline by Phase of Development, 2011
Figure 28: Anemia Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 29: Anemia Therapeutics - Technology Trends Analytics Framework, 2011
Figure 30: Anemia Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 31: Anemia Therapeutics - Clinical Trials by Country, 2011
Figure 32: Anemia Therapeutics - Clinical Trials by Phase, 2011
Figure 33: Anemia Therapeutics - Clinical Trials by Status, 2011
Figure 34: Anemia Therapeutics - Overall Sponsors, 2011
Figure 35: Anemia Therapeutics - Prominent Sponsors, 2011
Figure 36: Anemia Therapeutics Market - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 37: Anemia Market, Drivers and Restraints, 2011
Figure 38: Implications for Future Market Competition in Anemia Market, 2011
Figure 39: Anemia Therapeutics - Pipeline by Company, 2011
Figure 40: GlobalData Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Discovery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!